JNJ241213C148000
- 0.01
- 0.000.00%
Johnson & Johnson Newsroom
Bernstein Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Raises Target Price to $177
Johnson & Johnson (JNJ) Gets a Hold From Bernstein
Morgan Stanley Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Maintains Target Price $175
RBC Capital Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Maintains Target Price $181
Bernstein Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Maintains Target Price $161
Morgan Stanley Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Maintains Target Price $175
RBC Capital Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Maintains Target Price $181
Johnson & Johnson Analyst Ratings
Citi Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Cuts Target Price to $175
Johnson & Johnson Analyst Ratings
Wells Fargo Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Maintains Target Price $166
Johnson & Johnson's M&A Strategy in Cardiovascular Devices Supports Hold Rating
Morgan Stanley Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Maintains Target Price $175
Johnson & Johnson Initiated at Outperform by Wolfe Research
Johnson & Johnson Analyst Ratings
Wolfe Research Upgrades Johnson & Johnson(JNJ.US) to Buy Rating, Raises Target Price to $190
Johnson & Johnson Analyst Ratings
Guggenheim Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Cuts Target Price to $162
Guggenheim Adjusts Johnson & Johnson's Price Target to $162 From $156, Keeps Neutral Rating
Daiwa Securities Adjusts Price Target on Johnson & Johnson to $170 From $150, Maintains Neutral Rating